We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In September 2017, Roche’s Phase III eye drug lampalizumab failed to meet endpoints as a treatment for geographic atrophy (GA) due to age-related macular degeneration (AMD)